Agenda - Main Conference - Day 1 | Cell & Gene Therapy Manufacturing & Commercialization US

Showing 1 of 1 Streams

In Vivo Gene Therapy Manufacturing - Room 205AB

7:55am - 8:00am

Chairperson’s Opening Remarks

Morten Sogaard - President and Division Head, Gene Therapy Research and Technical Operations, Astellas Gene Therapies

8:00am - 8:40am

Keynote: State of the Industry and Future Perspectives for Cell and Gene Therapies

8:40am - 9:20am

Keynote: Partnering to Enable Industrialization of Allogeneic Cell Therapy

9:20am - 9:40am

A Robust Scalable Suspension Process for AAV Manufacturing

Samir Acharya - Associate Director of Process Development, Andelyn Biosciences

9:40am - 10:00am

Genomic Medicine Keeps Innovating. Manufacturing Should Too.

Showing 1 of 1 Streams

In Vivo Gene Therapy Manufacturing - Room 205AB

10:55am - 11:00am

Chairperson's Opening Remarks

11:00am - 11:30am

Keynote: Commercial Manufacturing Strategies for Large-Market and Rare Disease AAV Gene Therapy Products

11:30am - 12:00pm

Keynote – Addressing the Challenges of Transferring and Manufacturing Gene Therapies Externally and At-Scale

Ryan Bartock - VP & Head of Engineering, Technical & Digital, Spark Therapeutics

12:00pm - 12:30pm

How Novel Tools Can Accelerate AAV Development Timelines?

Yatindra Tirunagari - Business Development Technical Specialist, Rentschler Biopharma

Showing 1 of 1 Streams

In Vivo Gene Therapy Manufacturing - Room 205AB

1:55pm - 2:00pm

Chairperson’s Remarks

2:00pm - 2:30pm

The Only Constant is Change: Demonstrating Control and Comparability in Gene Therapy Products

2:30pm - 3:00pm

Build it Right: A Quality Perspective on the Design and Build of a Viral Vector CDMO Manufacturing Facility

3:00pm - 3:15pm

AAV Production with All-In-One Stable ELEVECTATM Producer Cell Lines – High Vector Quality At Large Scale

Vanessa Kress, PhD - Business Development Manager, CEVEC – now part of Cytiva

Main Conference - Day 1Tuesday, 19 September 2023 - EST/EDT (Eastern Daylight, GMT-4)